80
Participants
Start Date
June 6, 2024
Primary Completion Date
August 1, 2026
Study Completion Date
August 1, 2026
Vosoritide
Subcutaneous injection of recommended dose of vosoritide based on weight-band dosing once daily.
Placebo
Subcutaneous injection of recommended dose of placebo
Murdoch Children's Research Institute, Parkville
Nemours Alfred I. DuPont Hospital for Children, Wilmington
Children's National Medical Center, Washington D.C.
Medical College of Wisconsin, Milwaukee
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
University of Alberta Stollery Children's Hospital, Edmonton
SickKids - The Hospital for Sick Children, Toronto
Centre Hospitalier Universitaire Sainte-Justine, Montreal
Hospices Civils de Lyon - Hopital Femme Mere Enfant, Lyon
Hopital de la Timone, Marseille
Hopital Necker-Enfants Malade, Paris
CHU de Toulouse, Toulouse
Uniklinik Koln, Cologne
Univeristatskinderklinik Magdeburg, Magdeburg
Instituto Giannina Gaslini, Genoa
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome
Ospedale Pediatrico Bambino Gesu, Rome
Osaka University Hosptial, Osaka
Tokushima University Hospital, Tokushima
Institute of Science Tokyo Hospital, Tokyo
Tottori University Hospital, Tottori
Vithas Hospital San Jose, Vitoria-Gasteiz
Great Ormond Street Hospital for Children NHS Foundation Trust, London
Lead Sponsor
BioMarin Pharmaceutical
INDUSTRY